Skip to content
DraconiticResearch
Search Sources API
182,549 studies31 sourcesUpdated 52 min ago
Peer-reviewedCC BY 4.0International Journal of Molecular Sciences

Maleylated-BSA-Coated Gold Nanopopcorns for Pulmonary Delivery of Quercetin

  • Onkar Nigade1
  • Bala Prabhakar1
  • Francesco Trotta2
  • Pravin Shende1,3
  1. 1Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM’s NMIMS, Vile Parle (W), Mumbai 400056, India
  2. 2Department of Chemistry, University of Turin, Via Pietro Giuria 7, 10125 Torino, Italy
  3. 3National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali) 160062, India
Read full textPDFDOICite

Abstract

A non-motile bacterium, Mycobacterium tuberculosis (Mtb), causes tuberculosis (TB), an infection of the lower respiratory tract. Currently, rifampicin, isoniazid, ethambutol, and pyrazinamide are used as first-line treatment for drug-susceptible TB for two months, followed by four months of rifampicin and isoniazid. This treatment plan is linked to serious hepatic, dermatological, and hematopoietic adverse effects. The exploration of natural substances like quercetin for treating TB was driven by the significant side effects of the standard therapy protocol. Protein-coated gold nanopopcorns were developed as a dry-powder inhaler to deliver tailored medication to the lungs. The objective of this research article was to assess the effectiveness of quercetin-loaded gold nanopopcorns against Mtb H37Ra cells. The gold nanopopcorns prepared using the Turkevich method and subsequently coated with maleylated BSA (m-BSA) showed an adsorption efficiency of 87.02 ± 2.82%, particle size of 153.2 ± 26.45 nm, and a zeta potential of 29.3 ± 7.80 mV. In vitro release studies showed rapid initial release within 2 h, with a total drug release of 79.85 ± 1.33% over 24 h, with inhibition of 56.36% of H37Ra cells (IC50 = 2 μg/mL). These findings provide preliminary evidence for the potential of PNPs as a pulmonary quercetin delivery platform, warranting further evaluation in macrophage-based and tuberculosis disease models.

Related

  1. Coronary Drug-Coated Balloons as Brief-Contact Drug-Delivery Platforms: Engineering, Tissue Pharmacokinetics, and Angiographic/Imaging Response
    Grigorios Tsigkas, Antonios Rigas Papapanagiotou, Aggelos Papanikolaou +10
    Medicina (Kaunas, Lithuania)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Nano formulations of quercetin for ocular delivery.
    Mohd Nazil Salleh, Henkie Isahwan Ahmad Mulyadi Lai, Mohd Aizat Zain +1
    BioImpacts : BIPeer-reviewedCC BY-NCFull textPharmacology & toxicologyEurope PMC
  3. Enhanced Cutaneous Delivery of Quercetin Using Poloxamer 407–Cellulose Derivative Systems: A Topical Approach Aimed at Melanoma Therapy
    Gabrielli Furlan, Jéssica Bassi da Silva, Lidiane Vizioli de Castro Hoshino +3
    ACS OmegaPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefEurope PMCEurope PMCPMC
  4. Anti-PD-L1 antibody-coated metal-organic framework for targeted PTPN2 Inhibitor delivery and enhanced immunotherapy of head and neck squamous cell carcinoma
    Zhanpeng Zhu, Rui Wang, Wei Li +1
    International Journal of Pharmaceutics: XPeer-reviewedCC BY-NCFull textOncologyDOAJEurope PMCPMC
  5. Folic Acid-Functionalized Chitosan-Coated Oleosomes Engineered for Enhanced Anti-Arthritic Delivery of Syzygium cumini Seed Extract.
    Samar M Aborhyem, Neveen Agamy, Aamena F Abdallah +3
    Pharmaceuticals (Basel, Switzerland)Peer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{nigade2026maleylatedbsacoated,
  title = {{Maleylated-BSA-Coated Gold Nanopopcorns for Pulmonary Delivery of Quercetin}},
  author = {Onkar Nigade and Bala Prabhakar and Francesco Trotta and Pravin Shende},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  month = oct,
  doi = {10.3390/ijms27198808},
  url = {https://www.mdpi.com/1422-0067/27/19/8808},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Maleylated-BSA-Coated Gold Nanopopcorns for Pulmonary Delivery of Quercetin
AU  - Onkar Nigade
AU  - Bala Prabhakar
AU  - Francesco Trotta
AU  - Pravin Shende
PY  - 2026
DA  - 2026/10/01
JO  - International Journal of Molecular Sciences
DO  - 10.3390/ijms27198808
UR  - https://www.mdpi.com/1422-0067/27/19/8808
AB  - A non-motile bacterium, Mycobacterium tuberculosis (Mtb), causes tuberculosis (TB), an infection of the lower respiratory tract. Currently, rifampicin, isoniazid, ethambutol, and pyrazinamide are used as first-line treatment for drug-susceptible TB for two months, followed by four months of rifampicin and isoniazid. This treatment plan is linked to serious hepatic, dermatological, and hematopoietic adverse effects. The exploration of natural substances like quercetin for treating TB was driven by the significant side effects of the standard therapy protocol. Protein-coated gold nanopopcorns were developed as a dry-powder inhaler to deliver tailored medication to the lungs. The objective of this research article was to assess the effectiveness of quercetin-loaded gold nanopopcorns against Mtb H37Ra cells. The gold nanopopcorns prepared using the Turkevich method and subsequently coated with maleylated BSA (m-BSA) showed an adsorption efficiency of 87.02 ± 2.82%, particle size of 153.2 ± 26.45 nm, and a zeta potential of 29.3 ± 7.80 mV. In vitro release studies showed rapid initial release within 2 h, with a total drug release of 79.85 ± 1.33% over 24 h, with inhibition of 56.36% of H37Ra cells (IC50 = 2 μg/mL). These findings provide preliminary evidence for the potential of PNPs as a pulmonary quercetin delivery platform, warranting further evaluation in macrophage-based and tuberculosis disease models.
SN  - 1422-0067
ER  -